You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
CMEC Meeting 68, 15 August 2008
Complementary Medicines Evaluation Committee
Extracted ratified minutes
Public recommendation summary
This summary is posted shortly after the CMEC meeting to give quick notification of certain recommendations made by CMEC to the TGA. The TGA is yet to consider these recommendations and so this summary does not represent final decisions of TGA and should not be taken as such.
Reasons underlying these recommendations will be available after ratification of the Minutes at the next CMEC meeting. Other recommendations may be made at CMEC meetings but, because they concern confidential matters, or matters requiring further consideration by the TGA, they are not available for public disclosure.
CMEC confirms that the draft Minutes of its previous meeting (CMEC 67 20 June 2008), as amended, are a true and accurate record of that meeting.
CMEC recommends to the TGA that herbal preparations of the root, rhizome and/or stolons of Glycyrrhiza glabra and Glycyrrhiza uralensis are suitable as ingredients in Listed therapeutic products, subject to labelling advising of the potential for adverse effects in at-risk individuals, with wording to the effect:
- "Contains liquorice. Not suitable for people with a history of high blood pressure, or who are pregnant, or have kidney disease".
CMEC recommends to the TGA that only herbal preparations of the fruit resin of Daemonorops draco are suitable for use as an ingredient in Listed medicines.
CMEC recommends to the TGA that Listed medicines containing phytosterols require a label advisory statement with words to the effect:
- "There is no benefit from taking more than 3g/day of phytosterols from all sources"
- "Not suitable for pregnant or lactating women".
|CMEC 68 Extracted Ratified Minutes (pdf)||144KB|